About

Every signal a study produces deserves to be found and explained with all the evidence available.

Clinical, safety and operational. Synexis Life Sciences turns expert investigation into a governed capability every study can use.

Who we are

Synexis Life Sciences is a clinical technology company founded by two leaders with more than sixty combined years building and scaling enterprise clinical technology.

We built Reveal.IQ, an early signal discovery and governed investigation platform for clinical trials, for those who must know what is happening inside a study and have an answer for it.

Not a dashboard. Not a chatbot. The investigation itself.

Why we exist

Clinical trials do not lack data. They lack a fast, consistent way to understand what the data means.

The signal shows up in labs.
The context sits in adverse events.
The driver may be a concomitant medication, a dosing gap, a site's specimen handling, or the patient's own history.

The evidence exists. The story is scattered.

So an expert rebuilds it by hand, across six systems, over days, while patients are still being dosed.

Every person on our leadership team has either been a patient or cared for one. We have watched people we love spend years living with a burden that better answers might have shortened. That is why a delayed investigation is not an abstraction to us.

We are here to change how discoveries and investigations are done in clinical trials.

Who we serve

Those who must know what is happening inside a study and have answers for it.

  • Medical safety reviewers and medical monitors
  • Data managers and study monitors
  • Clinical operations and study leadership
  • Quality and regulatory teams
  • Sponsors, biotechs and CRO partners

Core beliefs

Detection is not investigation.Finding a signal is the beginning. The work is understanding what happened, what it means, and what to do about it.
Every patient deserves the same quality of investigation. The rigor a signal gets should not depend on which reviewer, CRO or sponsor happens to receive it. That changes when expert methods stop being individual know-how and become governed, reusable capabilities.
The expert decides.AI should carry the assembly and the explanation, never the judgment. The accountable human makes the call, every time.
Evidence should travel with the decision.A decision that matters should not live in screenshots, spreadsheets and memory.
Complexity belongs under the hood.A study team should not have to decode the system to see what matters.

Our story

SLS began with one observation.

The industry has spent years getting very good at capturing, cleaning and displaying clinical data. It is good at showing what changed. It is still slow at finding the patterns no rule was written for, and slow at answering what they mean.

Munther Baara and Peter Smilansky spent more than sixty combined years building that first generation: enterprise clinical platforms, CDISC adoption, clinical data repositories, metadata-driven review. They watched the same gap survive every technical upgrade. Once a signal appears, the investigation behind it is still assembled by hand, by scarce experts, in a way that varies by person, team and sponsor. A patient's outcome could turn on whether their signal reached the right reviewer on a good day.

So they built Reveal.IQ.

We started with hepatic safety, because drug-induced liver injury has been the single most frequent cause of safety-related drug withdrawals for the last fifty years. It is the highest-consequence investigation we could have picked, which is exactly why we picked it.

Munther Baara
Chief Strategy and Innovation Officer, Co-Founder

A pharma and technology leader who has worked at the front edge of clinical trial conduct, data sharing and multi-company collaboration.

Peter Smilansky
Chief Technology and Data Officer, Co-Founder

Deep expertise in clinical data architecture and the engineering of enterprise clinical platforms.

It does not just discover the signal. It reveals what it means.

Let's talk

info@synexisls.com